Madrigal Pharmaceuticals stock falls 1.80 percent as valuation stays high

Published on 09/22/2026 at 14:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Madrigal Pharmaceuticals stock closed at USD 521.96 on September 21, 2026, with a market value of USD 12.06 billion. The shares gained 227.23 percent year to date.

MDGL, US5563691094, Illustration mit AI erstellt.

Madrigal Pharmaceuticals, Inc. (US5563691094) closed at USD 521.96 on Nasdaq on September 21, 2026, down 1.80 percent on the session. The biotechnology company carried a market capitalization of USD 12.06 billion and a year-to-date gain of 227.23 percent in the latest available market snapshot.

Stock valuation remains elevated

The September 21, 2026 market data also show a five-day decline of 3.35 percent, while the shares remained 18.65 percent higher than at the start of the year. That combination puts the short-term pullback beside a much larger annual advance, making valuation and execution central to the stock story.

Madrigal Pharmaceuticals is classified in the biotechnology sector, and its Nasdaq listing uses the MDGL ticker. The market snapshot places the company at USD 12.06 billion in equity value, a figure that gives every operating update a direct valuation consequence.

Rezdiffra execution drives the case

Madrigal's commercial profile is tied to Rezdiffra, its metabolic-disease treatment, so revenue growth, prescription development and regulatory progress remain the operating measures most relevant to the valuation. The available September 2026 market data identify the company and its sector, while the latest directly matching search evidence does not provide a period-specific revenue or earnings figure that can be stated as a current result.

The quantified market comparison is clear: a 3.35 percent five-day decline contrasts with a 227.23 percent gain since the start of 2026. For investors, that spread matters because a high-growth biotechnology stock can remain sensitive to execution data even after a strong year-to-date revaluation.

Nasdaq price holds above USD 500

At USD 521.96 on September 21, 2026, Madrigal Pharmaceuticals stock remained above the USD 500 level while the latest sector comparison showed the company at approximately USD 12.06 billion in market capitalization. The price and capitalization are from the same market snapshot and refer to the Nasdaq listing.

The next market signal will come from a period-specific operating update that quantifies commercial progress and cash requirements. Until then, the dated price record, the 1.80 percent daily decline and the 227.23 percent year-to-date increase provide the clearest measurable frame for MDGL stock.